These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19323561)

  • 1. Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
    Ghosh AK
    J Med Chem; 2009 Apr; 52(8):2163-76. PubMed ID: 19323561
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
    Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ
    Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
    Mak CC; Le VD; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors.
    Innocenti R; Lenci E; Menchi G; Pupi A; Trabocchi A
    Bioorg Med Chem; 2017 Oct; 25(19):5077-5083. PubMed ID: 28359674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.
    Stamford A; Strickland C
    Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
    Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
    ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
    [No Abstract]   [Full Text] [Related]  

  • 11. Alzheimer's disease. A firm base for drug development.
    De Strooper B; König G
    Nature; 1999 Dec; 402(6761):471-2. PubMed ID: 10591201
    [No Abstract]   [Full Text] [Related]  

  • 12. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
    Ghosh AK; Dawson ZL; Mitsuya H
    Bioorg Med Chem; 2007 Dec; 15(24):7576-80. PubMed ID: 17900913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR.
    Fang WS; Sun DY; Yang S; Cheng C; Moschke K; Li T; Sun S; Lichtenthaler SF; Huang J; Wang Y
    Bioorg Chem; 2019 Nov; 92():103253. PubMed ID: 31557620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational drug design and HIV: hopes and limitations.
    Goody RS
    Nat Med; 1995 Jun; 1(6):519-20. PubMed ID: 7585113
    [No Abstract]   [Full Text] [Related]  

  • 16. Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization.
    Cumming J; Babu S; Huang Y; Carrol C; Chen X; Favreau L; Greenlee W; Guo T; Kennedy M; Kuvelkar R; Le T; Li G; McHugh N; Orth P; Ozgur L; Parker E; Saionz K; Stamford A; Strickland C; Tadesse D; Voigt J; Zhang L; Zhang Q
    Bioorg Med Chem Lett; 2010 May; 20(9):2837-42. PubMed ID: 20347593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protease inhibitors].
    Hamada Y; Kiso Y
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1702-7. PubMed ID: 18051403
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors.
    Guo T; Gu H; Hobbs DW; Rokosz LL; Stauffer TM; Jacob B; Clader JW
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3010-3. PubMed ID: 17418571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
    Cully M
    Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
    [No Abstract]   [Full Text] [Related]  

  • 20. [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
    Shitaka Y; Mitani Y; Nagakura A; Miyake A; Matsuoka N
    Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):15-20. PubMed ID: 20628208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.